Recursion Pharmaceuticals (RXRX) Receivables - Other (2021 - 2025)
Recursion Pharmaceuticals (RXRX) has disclosed Receivables - Other for 5 consecutive years, with $24.6 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Receivables - Other fell 49.87% year-over-year to $24.6 million, compared with a TTM value of $24.6 million through Dec 2025, down 49.87%, and an annual FY2025 reading of $24.6 million, down 49.87% over the prior year.
- Receivables - Other was $24.6 million for Q4 2025 at Recursion Pharmaceuticals, up from $21.9 million in the prior quarter.
- Across five years, Receivables - Other topped out at $49.2 million in Q4 2024 and bottomed at $2.1 million in Q1 2023.
- Average Receivables - Other over 5 years is $11.4 million, with a median of $7.7 million recorded in 2023.
- The sharpest move saw Receivables - Other plummeted 81.9% in 2023, then soared 1489.08% in 2024.
- Year by year, Receivables - Other stood at $9.1 million in 2021, then plummeted by 69.6% to $2.8 million in 2022, then rose by 12.39% to $3.1 million in 2023, then skyrocketed by 1489.08% to $49.2 million in 2024, then plummeted by 49.87% to $24.6 million in 2025.
- Business Quant data shows Receivables - Other for RXRX at $24.6 million in Q4 2025, $21.9 million in Q3 2025, and $21.6 million in Q2 2025.